Abstract:Liver Kinase B1 (LKB1), encoded by Serine-Threonine Kinase 11 ( STK11 ), is a master kinase that regulates cell migration, polarity, proliferation, and metabolism through downstream adenosine monophosphate-activated protein kinase (AMPK) and AMPK-related kinase signalling. Since genetic screens identified STK11 mutations in Peutz-Jeghers Syndrome, STK11 mutants have been implicated in tumourigenesis labelling it as a tumour suppressor. In support of this, several compounds reduce tumour burden through upregulating LKB1 signalling, and LKB1-AMPK agonists are cytotoxic to tumour cells. However, in certain contexts, its role in cancer is paradoxical as LKB1 promotes tumour cell survival by mediating resistance against metabolic and oxidative stressors. LKB1 deficiency has also enhanced the selectivity and cytotoxicity of several cancer therapies. Taken together, there is a need to develop LKB1-specific pharmacological compounds, but prior to developing LKB1 inhibitors, further work is needed to understand LKB1 activity and regulation. However, investigating LKB1 activity is strenuous as cell/tissue type, mutations to the LKB1 signalling pathway, STE-20-related kinase adaptor protein (STRAD) binding, Mouse protein 25-STRAD binding, splicing variants, nucleocytoplasmic shuttling, post-translational modifications, and kinase conformation impact the functional status of LKB1. For these reasons, guidelines to standardize experimental strategies to study LKB1 activity, associate proteins, spliced isoforms, post-translational modifications, and regulation are of upmost importance to the development of LKB1-specific therapies. Therefore, to assess the therapeutic relevancy of LKB1 inhibitors, this review summarizes the importance of LKB1 in cell physiology, highlights contributors to LKB1 activation, and outlines the benefits and risks associated with targeting LKB1.

Recent progress on liver kinase B1 (LKB1): expression, regulation, downstream signaling and cancer suppressive function.

Posttranslational regulation of liver kinase B1 in human cancer

Progress in antitumor mechanisms of liver kinase B1 gene

Role of the LKB1/AMPK pathway in tumor invasion and metastasis of cancer cells (Review)

LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors

LKB1 and Cancer: the Dual Role of Metabolic Regulation.

Under-expression of LKB1 is Associated with Enhanced P38-Mapk Signaling in Human Hepatocellular Carcinoma.

Advance of the research in the tumor suppressor gene LKB1

NUAK Kinases: Brain–Ovary Axis

Expression and transcriptional profiling of the LKB1 tumor suppressor in cervical cancer cells.

LKB1 and lung cancer: more than the usual suspects

Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α

Evaluation of liver kinase B1 downstream signaling expression in various breast cancers and relapse free survival after systemic chemotherapy treatment

LKB 1 / AMPK / Mtor Signaling Pathway in Non-small-cell Lung Cancer

Tumor Suppressor LKB1 Inhibits the Progression of Gallbladder Carcinoma and Predicts the Prognosis of Patients with This Malignancy

Cytoplasmic Liver Kinase B1 Promotes the Growth of Human Lung Adenocarcinoma by Enhancing Autophagy.

Liver kinase B1 regulates the centrosome via PLK1

Liver Kinase B1 Functions as a Regulator for Neural Development and a Therapeutic Target for Neural Repair

LKB1 reduces ROS-mediated cell damage via activation of p38

Skp2-dependent Ubiquitination and Activation of LKB1 is Essential for Cancer Cell Survival under Energy Stress.

AMPK as a metabolic tumor suppressor: control of metabolism and cell growth